title: Potent CTL induction by a whole cell pertussis vaccine in anti-tumor peptide immunotherapy.
abstract: Promising yet limited clinical responses have been reported for peptide based immunotherapy against tumors. In order to induce more potent cytolytic CD8 T cell responses, we investigated the use of Bordetella pertussis vaccine as an adjuvant for peptide immunization. A whole cell (Wc) vaccine has been known to induce a Th1 biased immune response while an acellular (Ac) vaccine tends to induce that of the Th2 type. Natural infection by B. pertussis helps to maintain a robust Th1 memory in the host population. To examine the adjuvant activity of the pertussis vaccine, we immunized mice with an ovalbumin peptide as a model tumor antigen, and monitored the development of anti-tumor activities. The addition of either the Ac or the Wc vaccine helped expand the specific CD8 T cells. However, there was a marked difference in the induced cytolytic activity where the Wc vaccine was superior to the Ac. The Wc vaccine was also more effective in inducing in vivo tumor rejection. The adjuvant activity was not only effective against ovalbumin, but was also evident when an endogenous tumor antigen, Wilms' tumor 1 gene product, was targeted. These results indicate that, although the Wc vaccine does not share the same antigen specificity with tumor cells, it can aid in the development of highly cytolytic CD8 T cells as an adjuvant at the site of peptide immunization.
authors.affiliation: Department of Immunology, Kochi Medical School, Nankoku, Japan.
authors.forename: Arisa
authors.initials: A
authors.lastname: Yano
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Komatsu
authors.forename: Masahide
authors.initials: M
authors.lastname: Ishibashi
authors.forename: Keiko
authors.initials: K
authors.lastname: Udaka
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D007167:Immunotherapy; D004915:Leukemia, Erythroblastic, Acute / Q000276:immunology / Q000628:therapy*; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010047:Ovalbumin / Q000276:immunology; D010455:Peptides / Q000276:immunology*; D010567:Pertussis Vaccine / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D022282:Vaccines, Acellular / Q000276:immunology; D025721:WT1 Proteins / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D010455:Peptides; D010567:Pertussis Vaccine; D022282:Vaccines, Acellular; D025721:WT1 Proteins; D010047:Ovalbumin